Skip to main content

Tourmaline Bio, Inc.

TRMLDelisted Oct 28, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001827506

Tourmaline Bio, Inc. was delisted on Oct 28, 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.

Q4 2022 vs. Q3 2022

How the institutions holding Tourmaline Bio, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of TRML: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders5654−2
Shares27.3M26.8M−463.8K (−1.7%)
Value$72.1M$27.4M−$44.7M (−62.0%)

New holders (10)

Institutions that held Tourmaline Bio, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to TRML in Q4 2022
InstitutionSharesValue% of portfolio
Marquette Asset Management, LLC79,381$81.0K0.02%
Ergoteles LLC43,522$44.4K0.00%
Two Sigma Advisers, LP33,700$34.4K0.00%
Squarepoint Ops LLC28,084$28.6K0.00%
Chicago Partners Investment Group LLC14,834$26.2K0.00%
Renaissance Technologies LLC20,800$21.0K0.00%
Virtu Financial LLC16,372$17.0K0.00%
Alliancebernstein L.P.13,600$13.9K0.00%
UBS Group AG11,092$11.3K0.00%
Federated Hermes, Inc.1,680$1.71K0.00%

Sold out (12)

Institutions that held Tourmaline Bio, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.